JP2012508784A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508784A5
JP2012508784A5 JP2011543797A JP2011543797A JP2012508784A5 JP 2012508784 A5 JP2012508784 A5 JP 2012508784A5 JP 2011543797 A JP2011543797 A JP 2011543797A JP 2011543797 A JP2011543797 A JP 2011543797A JP 2012508784 A5 JP2012508784 A5 JP 2012508784A5
Authority
JP
Japan
Prior art keywords
particulate material
material according
particulate
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011543797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508784A (ja
Filing date
Publication date
Priority claimed from FR0857763A external-priority patent/FR2938431B1/fr
Application filed filed Critical
Publication of JP2012508784A publication Critical patent/JP2012508784A/ja
Publication of JP2012508784A5 publication Critical patent/JP2012508784A5/ja
Pending legal-status Critical Current

Links

JP2011543797A 2008-11-14 2009-11-10 γ−ヒドロキシ酪酸に基づく新規の組成物 Pending JP2012508784A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0857763A FR2938431B1 (fr) 2008-11-14 2008-11-14 Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR0857763 2008-11-14
PCT/FR2009/052169 WO2010055260A1 (fr) 2008-11-14 2009-11-10 Nouvelle composition à base d'acide gamma-hydroxybutyrique

Publications (2)

Publication Number Publication Date
JP2012508784A JP2012508784A (ja) 2012-04-12
JP2012508784A5 true JP2012508784A5 (enExample) 2016-05-26

Family

ID=40674006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011543797A Pending JP2012508784A (ja) 2008-11-14 2009-11-10 γ−ヒドロキシ酪酸に基づく新規の組成物

Country Status (34)

Country Link
US (1) US8529954B2 (enExample)
EP (1) EP2349217B1 (enExample)
JP (1) JP2012508784A (enExample)
KR (1) KR101563390B1 (enExample)
CN (2) CN104688691A (enExample)
AR (1) AR074351A1 (enExample)
AU (1) AU2009315441B2 (enExample)
BR (1) BRPI0916021B8 (enExample)
CA (1) CA2743767C (enExample)
CL (1) CL2011001114A1 (enExample)
CO (1) CO6382106A2 (enExample)
CU (1) CU20110109A7 (enExample)
CY (1) CY1122209T1 (enExample)
DK (1) DK2349217T3 (enExample)
EA (1) EA023305B1 (enExample)
ES (1) ES2749803T3 (enExample)
FR (1) FR2938431B1 (enExample)
HR (1) HRP20191911T1 (enExample)
HU (1) HUE046321T2 (enExample)
IL (1) IL212847A (enExample)
LT (1) LT2349217T (enExample)
MA (1) MA32790B1 (enExample)
MX (1) MX2011005073A (enExample)
NZ (1) NZ592850A (enExample)
PE (1) PE20120028A1 (enExample)
PL (1) PL2349217T3 (enExample)
PT (1) PT2349217T (enExample)
SI (1) SI2349217T1 (enExample)
SM (1) SMT201900721T1 (enExample)
TN (1) TN2011000231A1 (enExample)
TW (1) TWI446906B (enExample)
UA (1) UA103057C2 (enExample)
WO (1) WO2010055260A1 (enExample)
ZA (1) ZA201103542B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CN111511355A (zh) * 2017-12-20 2020-08-07 弗拉梅爱尔兰有限公司 具有改善稳定性的γ-羟基丁酸盐的包装改性释放制剂
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) * 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 4-纈胺醯氧基丁酸的合成方法
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
CN115038432B (zh) * 2020-06-18 2023-12-26 凯瑞康宁生物工程(武汉)有限公司 水溶性活性药物成分的控制释放制粒
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
CN112868909A (zh) * 2021-01-22 2021-06-01 湖北神舟化工有限公司 一种无臭型丁酸钠及其生产方法
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ-ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
CN117157060A (zh) * 2021-04-16 2023-12-01 南京纽邦生物科技有限公司 包衣β-羟基丁酸晶体及其制备方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド 1晩1回の低ナトリウムオキシベート組成物
CN117413958B (zh) * 2023-12-04 2026-02-03 湖北中烟工业有限责任公司 一种加热不燃烧烟草制品发烟段物料及其制作工艺和加热不燃烧烟草制品

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101650A (en) 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) * 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US6214386B1 (en) 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
JP3447042B2 (ja) * 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
GB9725219D0 (en) 1997-11-29 1998-01-28 Cleansharp Ltd Tablets
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
CA2355293C (en) * 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
CA2374356C (fr) * 1999-05-17 2012-01-03 D.B.F. Granules contenant une substance vegetale et leur procede de preparation
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
CA2456322A1 (en) 2001-08-06 2003-02-20 Euro-Celtique, S.A. Compositions and methods to prevent abuse of opioids
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829933B3 (fr) 2001-09-21 2004-03-12 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs notamment de gout et produit obtenu
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
CA2558535A1 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
TW200533391A (en) 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) * 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
ZA200711123B (en) 2005-06-27 2009-08-26 Biovail Lab Int Srl Modified-release formulations of a bupropion salt
US20070092565A1 (en) 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US9149434B2 (en) * 2007-12-03 2015-10-06 Tomita Pharmaceutical Co., Ltd. Core particle for pharmaceutical preparation
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants

Similar Documents

Publication Publication Date Title
JP2012508784A5 (enExample)
TWI446906B (zh) 以γ-羥基丁酸為基礎的新穎組成物
JP6068142B2 (ja) 浮遊微粒剤
JP2013501717A5 (enExample)
JP2013501718A5 (enExample)
CN101987082A (zh) 固体制剂及其制备方法
JP2007509891A5 (enExample)
JP2004531399A5 (enExample)
JP2012508786A5 (enExample)
JP2005112845A (ja) 二層構造を有するエディブルシート
CN102048701B (zh) 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法
JP2017071605A5 (enExample)
JP5608681B2 (ja) 活性成分の粒状物質を製造する新規の方法、及びそれにより得られた粒状物質
JP4364869B2 (ja) 咀嚼性カプセルの製造方法
WO2016088816A1 (ja) 酢酸亜鉛水和物錠及びその製造方法
US20070184099A1 (en) Films for use as dosage forms
CN104739775A (zh) 一种新的盐酸文拉法辛缓释小丸及其制备方法
WO2009063320A3 (es) Composición farmacéutica sólida de didanosina